Phenotypes of idiopathic pulmonary arterial hypertension
- PMID: 36179742
- DOI: 10.1016/S2213-2600(22)00308-3
Phenotypes of idiopathic pulmonary arterial hypertension
Conflict of interest statement
RB reports personal fees from UT, Dompè, Ferrer, Bayer, MSD, AOP, and Orphan Pharmaceuticals, outside of the submitted work. RLB reports grants from Actelion, Bayer, Bellerophon, Eiger, and Abbott. GM declares no competing interests. KT has received speaking fees from Actelion and Bayer, outside of the submitted work. RN reports relationships including consultancies, speaker's fees, and membership of advisory boards with AOP, Orphan Pharmaceuticals, Johnson & Johnson, Lung Biotechnology Corporation, and United Therapeutics. All authors contributed to writing of this Correspondence and approved the manuscript for submission.
Comment in
-
Phenotypes of idiopathic pulmonary arterial hypertension - Authors' reply.Lancet Respir Med. 2022 Oct;10(10):e90-e91. doi: 10.1016/S2213-2600(22)00273-9. Lancet Respir Med. 2022. PMID: 36179743 No abstract available.
Comment on
-
Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis.Lancet Respir Med. 2022 Oct;10(10):937-948. doi: 10.1016/S2213-2600(22)00097-2. Epub 2022 Jun 28. Lancet Respir Med. 2022. PMID: 35777416 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical